NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,843.98 mln
Float116 mln
Earnings Date08/12/2026
EPS
1.73
Moderate
P / E
18.14
Moderately valued
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-1.84
Caution advised
1-Year Forecast
31.67
Fairly priced
Relative Strength
61
/ 100
Outperforming
Business Description
Catalyst Pharmaceuticals is a Florida-based company that develops and sells treatments for patients with rare and serious medical conditions. Its current portfolio includes three approved medicines targeting nerve and muscle disorders, including Lambert-Eaton myasthenic syndrome, certain types of epilepsy, and Duchenne muscular dystrophy. The company also works with outside partners to expand its reach through licensing and development agreements.